CEO Emily Leproust Files Form 144 to Sell $44.7M of Twist Bioscience Stock
TWST has more than doubled off its 52-week low of $23.3 on elevated volume (1.9× avg).
Summary
CEO Emily Leproust intends to sell $44.7M of Twist Bioscience stock under a 10b5-1 plan, including shares from a fresh option exercise, while the stock trades near its 52-week high.
Key Events · Ownership and Investor Activity · TWST
-
CEO Files $44.7M Form 144
Emily Leproust intends to sell 295,037 shares valued at approximately $44.7 million, a materially larger sale than the $9.3 million disclosed in a concurrent Form 144 filing.
-
Includes Fresh Option Exercise
The proposed sale includes 208,708 shares from a stock option exercise dated September 17, 2026, indicating liquidation of a new equity tranche.
-
Part of 10b5-1 Plan
The sale is executed under a pre-existing 10b5-1 trading plan adopted June 15, 2026, covering up to 720,906 shares as previously disclosed in the August 3, 2026 10-Q.
-
Recent Sales History
Leproust has already sold 209,450 shares for approximately $26.6 million in the past three months under the same plan.
Analysis · TWST · Life Sciences
CEO Emily Leproust has filed a Form 144 to sell 295,037 shares worth approximately $44.7 million, a substantially larger sale than the $9.3 million disclosed in a concurrent filing. The sale includes 208,708 shares from a stock option exercise dated today, indicating she is liquidating a new tranche of equity. This is part of a pre-existing 10b5-1 plan adopted June 15, 2026, but the size — roughly 0.44% of shares outstanding — is notable for a CEO, especially with the stock trading near its 52-week high.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 29.5% of the 1699 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TWST was trading at $155.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $23.30 to $163.70. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.